γ-H2AX as a biomarker for DNA double-strand breaks in ecotoxicology

Ecotoxicology and Environmental Safety

Volumn 105, Issue 1, 2014, Pages 13-21

  Gerić, Marko ^a   Gajski, Goran ^a   Garaj Vrhovac, Vera ^a  

^a INSTITUTE FOR MEDICAL RESEARCH AND OCCUPATIONAL HEALTH   (Croatia)

Author keywords

Cytostatic pharmaceuticals; Double strand breaks; Environmental concentrations; Genotoxicity; H2AX foci assay

Indexed keywords

APHIDICOLIN; BETA LAPACHONE; BLEOMYCIN; CISPLATIN; CYTARABINE; CYTOSTATIC AGENT; DEMECOLCINE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GEFITINIB; GEMCITABINE; HISTONE GAMMA H2AX; HISTONE H2AX; IMATINIB; IRINOTECAN; METHOTREXATE; MITOMYCIN; MITOXANTRONE; PACLITAXEL; TOPOTECAN; UNCLASSIFIED DRUG; VINCRISTINE; ZIDOVUDINE;

AQUATIC ECOSYSTEM; BIOASSAY; BIOMARKER; BIOMONITORING; CONCENTRATION (COMPOSITION); DNA; DRUG; ECOTOXICOLOGY; GENOTOXICITY; PROTEIN; RISK ASSESSMENT; VISUALIZATION; WASTE DISPOSAL; WASTEWATER; WATER QUALITY;

ARTICLE; BIOLOGICAL MONITORING; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; DOUBLE STRANDED DNA BREAK; DRUG CYTOTOXICITY; DRUG INDUSTRY; ECOTOXICOLOGY; GAMMA H2AX GENE; GENE IDENTIFICATION; GENETIC MARKER; GENOME ANALYSIS; GENOTOXICITY; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; NONHUMAN; PHARMACOGENETICS; RISK ASSESSMENT; SENSITIVITY ANALYSIS; TOXICITY TESTING; TOXICOKINETICS; WASTE WATER; WATER POLLUTION;

CYTOSTATIC PHARMACEUTICALS; DOUBLE-STRAND BREAKS; ENVIRONMENTAL CONCENTRATIONS; GENOTOXICITY; Γ-H2AX FOCI ASSAY;

ANIMALS; BIOLOGICAL MARKERS; CYTOSTATIC AGENTS; DNA; DNA BREAKS, DOUBLE-STRANDED; ECOTOXICOLOGY; HISTONES; HUMANS;

EID: 84900528298     PISSN: 01476513     EISSN: 10902414     Source Type: Journal    
DOI: 10.1016/j.ecoenv.2014.03.035     Document Type: Article

References (124)

1. Aardema M.J., Albertini S., Arni P., Henderson L.M., Kirsch-Volders M., Mackay J.M., Sarrif A.M., Stringler D.A., Taalman R.D. Aneuploidy: a report of an ECETOC task force. Mutat. Res. 1998, 410:3-79.
2. Albino A.P., Huang X., Jorgensen E., Yang J., Gietl D., Traganos F., Darzynkiewicz Z. Induction of H2AX phosphorylation in pulmonary cells by tobacco smoke: a new assay for carcinogens. Cell Cycle 2004, 3:1062-1068.
3. Audebert M., Riu A., Jacques C., Hillenweck A., Jamin E.L., Zalko D., Cravedi J.P. Use of the gamma H2AX assay for assessing the genotoxicity of polycyclic aromatic hydrocarbons in human cell lines. Toxicol. Lett. 2010, 199:182-192.
4. Avondoglio D., Scott T., Kil W.J., Sproull M., Topfilon P.J., Camphausen K. High throughput evaluation of gamma-H2AX. Radiat. Oncol. 2009, 4:31.
5. Azarova A.M., Lyu Y.L., Lin C.P., Tsai Y.C., Lau J.Y., Wang J.C., Liu L.F. From the cover: roles of DNA topoisomerase II izozymes in chemotherapy and secondary malignancies. Proc. Natl. Acad. Sci. USA 2007, 104:11014-11019.
6. Banáth J.P., Klokov D., MacPhail S.H., Banuelos C.A., Olive PL. Residual gammaH2ax foci as an indicator of lethal DNA lesions. BMC Cancer 2010, 10:4. 10.1186/1471-2407-10-4.
7. Baun A., Hartmann N.B., Grieger K., Kusk K.O. Ecotoxicity of engineered nanoparticles to aquatic invertebrates: a brief review and recommendations for future toxicity testing. Ecotoxicology 2008, 17:387-395.
8. Beels L., Bacher K., De Wolf D., Werbrouck J., Thierens H. γ-H2AX foci as biomarker for patient X-ray exposure in pediatric cardiac catheterization: are we underestimating radiation risks?. Circulation 2009, 120:1903-1909.
9. Bekker-Jensen S., Mainland N. Assembly and function of DNA double-strand break repair foci in mammalian cells. DNA Repair 2010, 9:1219-1228.
10. Belyaev I.Y., Markovà E., Hillert L., Malmgren L.O., Persson B.R. Microwaves from UMTS/GSM mobile phones induce long-lasting inhibition of 53BP1/γH2AX DNA repair foci in human lymphocytes. Bioelectromechanics 2009, 30:129-141.
11. Besse J.P., Latour J.F., Garric J. Anticancer drugs in surface waters: what can we say about the occurrence and environmental significance of cytotoxic, cytostatic and endocrine therapy drugs?. Environ. Int. 2012, 39:73-86.
12. Bolognesi C., Hayashi M. Micronucleus assay in aquatic animals. Mutagenesis 2011, 26:205-213.
13. Brzozowska K., Pinkawa M., Eble M.J., Müller W.U., Wojcik A., Kriehuber R., Schmitz S. in vivo versus in vitro individual radiosensitivity analysed in healthy donors and in prostate cancers patients with and without severe side effects after radiotherapy. Int. J. Biol. 2012, 88:405-413.
14. Charbonnel C., Allain E., Gallego M.E., White C.I. Kinetis analysis of DNA double-strand break repair pathways in Arabidopsis. DNA Repair 2011, 10:611-619.
15. Chaudhry M.A. Biomarkers for human radiation exposure. J. Biomed. Sci. 2008, 15:557-563.
16. Chu P.M., Chiou S.H., Su T.L., Lee Y.J., Chen L.H., Chen Y.W., Yen S.H., Chen M.H., Chen M.T., Shih Y.H., Tu P.H., Ma H.I. Enhancement of radiosensitivity in human glioblastoma cells by the DNA N-mustard alkylating agent BO-1051 through augmented and sustained DNA damage response. Radiat. Oncol. 2011, 6:7.
17. Clingen P.H., Wu J.Y.H., Miller J., Mistry N., Chin F., Wynne P., Prise K.M., Hartley J.A. Histone H2AX phosphorylation as a molecular pharmacological marker for DNA interstrand crosslink cancer chemotherapy. Biochem. Pharmacol. 2008, 76:19-27.
18. Collins A.R., Oscoz A.A., Brunborg G., Gaivão I., Giovannelli L., Kruszewski M., Smith C.C., Stetina R. The comet assay: topical issues. Mutagenesis 2008, 23:143-151.
19. Delgado L.F., Charles P., Glucina K., Morlay C. QSAR-like models: a potential tool for selection of PhACs and EDCs for monitoring purposes in drinking water treatment systems - a review. Water Res. 2012, 46:6196-6209.
20. Dickey J.S., Redon C.E., Nakamura A.J., Baird B.J., Sedelinkova O.A., Bonner W.M. H2AX: functional roles and potential applications. Chromosoma 2009, 118:683-692.
21. Dmitrieva N.I., Burg M.B. Analysis of DNA breaks, DNA damage response, and apoptosis produced by high NaCl. Am. J. Physiol. Renal Physiol. 2008, 295:F1678-F1688.
22. Dorr R.T. Bleomycin pharmacology: mechanism of action and resistance, and clinical pharmacokinetics. Semin. Oncol. 1992, 19:3-8.
23. Enger E.D., Ross F.C., Bailey D.B. Concepts in Biology. Cell division - replication and reproduction 2007, 163-190. McGraw-Hill, NY. twelfth ed.
24. Ewald B., Sampath D., Plunkett W. H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation. Mol. Cancer Therap. 2007, 6:1239-1248.
25. Ewald B., Sampath D., Plunkett W. ATM and the Mre11-Rad50-Nbs1 complex respond to nucleoside analogue-induced stalled replication forks and contribute to drug resistance. Cancer Res. 2008, 68:7947-7955.
26. Fenech M. Cytokinesis-block micronucleus assay evolves into a "cytome" assay of chromosomal instability, mitotic dysfunction and cell death. Mutat. Res. 2006, 600:58-66.
27. Fenech M. Cytokinesis-block micronucleus sytome assay. Nat. Protoc. 2007, 2:1084-1104.
28. Fenech M. The lymphocytes cytokinesis-block micronucleus cytome assay and its application in radiation biodosimetry. Health Phys. 2010, 98:234-243.
29. Filipič, M., Isidori, M., Knasmüller, S., Horvath, A., Garaj-Vrhovac, V., Baebler, Š., Gačić, Z., 2013. Environment occurrence and potential adverse effects of residues of cytostatic drugs to aquatic organisms. UNESCO Conference on Emerging Pollutants in Water, Belgrade, Serbia, 9-11 July 2013.
30. Fuji Y., Yurkon C.R., Maeda J., Genet S.C., Kubota N., Fujimori A., Mori T., Maruo K., Kato T.A. Comparative study of radioresistance between feline cells and human cells. Radiat. Res. 2013, 180:70-77.
31. Galluzzi L., Moselli E., Vitale I., Kepp O., Senovilla L., Criollo A., Servant N., Paccard C., Hupé P., Robert T., Ripoche H., Lazar V., Harel-Bellan A., Dessen P., Barillot E., Kroemer G. miR-181a and miR-630 regulate cisplatin-induced cancer cell death. Cancer Res. 2010, 70:1793-1803.
32. Garcia-Canton C., Anadon A., Meredith C. Assessment of the in vitro γH2AX assay by high content screening as a novel genotoxicity test. Mutat. Res. 2013, 757:158-166.
33. Garcia-Sagredo J.M. Fifty years of cytogenetics: Aparallel view of the evolution of cytogenetics and genotoxicology. Biochim. Biophys. Acta 2008, 1779:363-375.
34. Garty G., Chen Y., Salerno A., Turner H., Zhang J., Lyulko O., Bertucci A., Xu Y., Wang H., Simaan N., Randers-Pehrson G., Yao Y.L., Amundson S.A., Brenner D.J. The RABIT: A rapid automated biodosimetry tool for radiological triage. Health Phys. 2010, 98:209-217.
35. Garty G., Chen Y., Turner H., Zhang J., Lyulko O., Bertucci A., Xu Y., Wang H., Simaan N., Randers-Pehrson G., Yao Y.L., Brenner D.J. The RABiT: a rapid automated biodosimetry tool for radiological triage. II. Technological developments. Int. J. Radiat. Biol. 2011, 87:776-790.
36. Hande K.R. Etoposide: four decades of development of a topoisomerase II inhibitor. Eur. J. Cancer 1998, 34:1514-1521.
37. Hamasaki K., Imai K., Nakachi K., Takahashi N., Kodama Y., Kusunoki Y. Short-term culture and γ-H2AX flow cytometry determine differences in individual radiosensitivity in human peripheral T lymphocytes. Environ. Mol. Mutagen. 2007, 48:38-47.
38. Hecht S.M. Bleomycin: new perspectives on the mechanism of action. J. Nat. Prod. 2000, 63:158-168.
39. Hernando M.D., Mezcua M., Fernández-Alba A.R., Barceló D. Environmental risk assessment of pharmaceutical residues in wastewater effluents, surface waters and sediments. Talanta 2006, 69:334-342.
40. Huang X., Okafuji M., Traganos F., Luther E., Holden E., Darzynkiewicz Z. Assessment of Histone H2AX phosphorylation induced by topoisomerase I and II inhibitors topotecan and mitoxantrone and by the DNA cross-linking agent cisplatin. Cytometry A 2004, 58:99-110.
41. International Atomic Energy Agency (IAEA), 1986. Biological dosimetry: chromosomal aberration analysis for dose assessment. Technical Report Series 260 (Vienna: IAEA).
42. Ikeda M., Kurose A., Takatori E., Sugiyama T., Traganos F., Darzynkiewicz Z., Sawai T. DNA damage detected with γH2AX in endometroid adenocarcinoma cell lines. Int. J. Oncol. 2010, 36:1081-1088.
43. Ismail I.H., Wadhra T.I., Hammarsten O. An optimized method for detecting gamma-H2AX in blood cells reveals a significant interindividual variation in the gamma-H2AX response among humans. Nucleic Acids Res. 2007, 35:e36.
44. Ivashkevich A.N., Martin O.A., Smith A.J., Redon C.E., Bonner W.M., Martin R.F., Lobachevsky P.N. γ-H2AX foci as a measure of DNA damage: a computational approach to automatic analysis. Mutat. Res. 2011, 711:49-60.
45. Jayachandran G., Ueda K., Wang B., Roth J., Ji L. NPRL2 sensities human non-small cell lung cancer (NSCLC) cells to cisplatin treatment by regulating key components in the DNA repair pathway. PLoS One 2010, 5:e11994.
46. Jost G., Golfier S., Pietsch H., Lengsfeld P., Voth M., Schmid T.E., Eckardt-Schupp F., Schmid The influence of x-ray contrast agents in computed tomography on the induction of dicentrics and γ-H2AX foci in lymphocytes of human blood samples. Phys. Med. Biol. 2009, 54:6029-6039.
47. Kang L., Chung B.G., Langer R., Khademhosseini A. Microfluidics for drug discovery and development: from target selection to product lifecycle management. Drug Discov. Today 2008, 13:1-13.
48. Katzung B.G. Section I. Basic principles. Basic & Clinical Pharmacology 1992, 4-5. Prentice-Hall International Inc., East Norwalk. B.G. Katzung (Ed.).
49. Kim S., Jun D.H., Kim H.J., Jeong K.C., Lee C.H. Development pf a high-content screening method for chemicals modulating DNA damage response. J. Biomol. Screen. 2011, 16:259-265.
50. Kinner A., Wu W., Staudt C., Iliakis G. γ-H2AX in recognition and signalling of DNA double-strand breaks in the context of chromatin. Nucleic Acids Res. 2008, 36:5678-5694.
51. Kobayashi Y. Molecular mechanism of the recruitment of NBS1/hMRE11/hRAD50 complex to DNA double-strand breaks: NBS1 binds to γ-H2AX through FHA/BRCT domain. J. Radiat. Res. 2004, 45:473-478.
52. Kobayashi J., Iwabuchi K., Miyagawa K., Sonoda E., Suzuki K., Takata M., Tauchi H. Current topics in DNA double-strand break repair. J. Radiat. Res. 2008, 49:93-103.
53. Kosjek T., Perko S., Žigon D., Heath E. Fluorouracil in the environment: analysis, occurrence, degradation and transformation. J. Chromatogr. A. 2013, 17:62-72.
54. Kuo L.J., Yang L.X. Gamma-H2AX - a novel biomarker for DNA double-strand breaks. in vivo 2008, 22:305-309.
55. Lenz K., Koellensperger G., Hann S., Weissenbacher N., Mahnik S.N., Fuerhacker Fate of cancerostatic platinum compounds in biological wastewater treatment of hospital effluents. Chemosphere 2007, 69:1765-1774.
56. Leopardi P., Cordelli E., Villani P., Cremona T.P., Conti L., De Luca G., Crebelli R. Assessment of in vivo genotoxicity of the rodent carcinogen furan: evaluation of DNA damage and induction of micronuclei in mouse splenocytes. Mutagenesis 2010, 25:57-62.
57. Li L., Wang H., Yang E.S., Arteaga C.L., Xia F. Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cells. Cancer Res. 2008, 68:9141-9146.
58. 2 in an aqueous environment. Water Res. 2014, 48:559-568.
59. Liu Y., Tseng M., Perdreau S.A., Rossi.F., Antonescu C., Besmer P., Fletcher J.A., Duensing S., Duensing A. Histone H2AX is a mediator of gastrointestinal stromal tumor cell apoptosis following treatment with imatinib mesylate. Cancer Res. 2007, 67:2685-2692.
60. Löbrich M., Shibata A., Beucher A., Fisher A., Ensminger M., Goodarzi A.A., Barton O., Jeggo P.A. GammaH2AX foci assay analysis for monitoring DNA double-strand break repair: strengths, limitations and optimization. Cell Cycle 2010, 9:662-669.
61. Maekawa T., Ashihara E., Kimura S. The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias. Int. J. Clin. Oncol. 2007, 12:327-340.
62. Mahnik S.N., Lenz K., Weissenbacher N., Mader R.M., Fuerhacker M. Fate of 5-fluorouracil, doxorubicin, epirubicin and danorubicin in hospital wastewater and their elimination by activated sludge and treatment in a membrane-bio-reactor system. Chemosphere 2007, 66:30-37.
63. Matsuzaki K., Harada A., Takeiri A., Tanaka K., Mishima M. Whole cell-ELISA to measure the γH2AX response of six aneugens and eight DNA-damaging chemicals. Mutat. Res. 2010, 700:71-79.
64. Mattsson A., Lundstedt S., Stenius U. Exposure of HepG2 cells to low levels of PAH-containing extracts from contaminated soils results in unpredictable genotoxic stress responses. Environ. Mol. Mutagen. 2009, 50:337-348.
65. Minter-Dykhouse K., Ward I., Huen M.S.Y., Chen J., Lou Z. Distinct versus overlapping functionsof MDC1 and 53BP1 in DNA damage response and tumorigenesis. J. Cell Biol. 2008, 182:693-705.
66. Mitchelmore C.L., Chipman J.K. DNA strand breakage in aquatic organisms and the potential value of the comet assay in environmental monitoring. Mutat. Res. 1998, 399:135-147.
67. Mondal N.K., Mukherjee B., Das D., Ray M.R. Micronucleus formation, DNA damage and repair in premenopausal women chronically exposed to high level of indoor air pollution from biomass fuel use in rural India. Mutat. Res. 2010, 697:47-54.
68. Muslimović A., Nyström S., Gao Y., Hammarsten O. Numerical analysis of etoposide induced DNA breaks. PLoS One 2009, 4:e5859.
69. Nagelkerke A., van Kuijk S.J., Sweep F.C., Nagtegaal I.D., Hoogerbrugge N., Martens J.W., Timmermans M.A., van Laarhoven H.W., Bussink J., Span P.N. Constitutive expression of γ-H2AX has prognostic revelaance in triple negative breast cancer. Radiother. Oncol. 2011, 101:39-45.
70. Negreira N., López de Alda M., Barceló D. On-line solid phase extraction-liquid chromatography-tandem mass spectrometry for the determination of 17 cytostatics amd metabolites in waste, surface and ground water samples. J. Chromatogr. A 2013, 1280:64-74.
71. Negreira N., Mastroianni N., López de Alda M., Barceló D. Multianalyte determination of 24 cytostatics and metabolites by liquid chromatography-electrospray-tandem mass spectrometry and study of their stability and optimum storage condition in aqueous solution. Talanta 2013, 116:290-299.
72. Obe G., Pfeifer P., Savage J.R., Johannes C., Goedecke W., Jeppesen P., Natarajan A.T., Martínez-López W., Folle G.A., Drets M.E. Chromosomal aberrations: formation, identification and distribution. Mutat. Res. 2002, 504:17-36.
73. Olive P.L., Banáth J.P. Kinetics of H2AX phosphorylation after exposure to cisplatin. Cytom. B Clin. Cytom 2009, 76:79-90.
74. Paull T.T., Rogakou E.P., Yamazaki V., Kirchgessner U., Gellert M., Bonner W.M. A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Curr. Biol. 2000, 10:886-895.
75. Peterson-Roth E., Reynolds M., Quievryn G., Zhitkovich Mismatch repair proteins are activators of toxic responses to chromium-DNA damage. Mol. Cell Biol. 2005, 25:3596-3607.
76. Pospelova T.V., Demidenko Z.N., Bukreeca E.I., Pospelov V.A., Gudkov A.V., Blagosklonny M.V. Pseudo-DNA damage response in senescent cells. Cell Cycle 2009, 8:4112-4118.
77. Rakiman I.M., Chinnadurai M., Baraneedharan U., Paul S.F.D., Venkatachalam P. γ-H2AX assay: a technique to quantify DNA double strand breaks. Adv. Biotech 2008, 39-41.
78. Redon C.E, Nakamura A.J., Gouliaeva K., Rahman A., Blakely W.F., Bonner W.M. The use of gamma-H2AX as a biodosimeter for total-body radiation exposure in non- human primates. PLoS One 2010, 5:e15544.
79. Redon C.E, Dickey J.S., Nakamura A.J., Kareva I.G., Naf D., Nowsheen S., Kryston T.B., Bonner W.M., Georgakilas A.G., Sedelinkova O.A. Tumors induce complex DNA damage in distant proliferative tissues in vivo. Proc. Natl. Acad. USA 2010, 107:17992-17997.
80. Redon C.E, Nakamura A.J., Martin O.A., Parekh P.R., Weyemi U.S., Bonner W.M. Recent developments in the use of γ-H2AX as a quantitative DNA double-strand break biomarker. Aging 2011, 3:168-174.
81. Redon C.E., Nakamura A.J., Sordet O., Dickey J.S., Gouliaeva K., Tabb B., Lawrence S., Kinders R.J., Bonner W.M., Sedelinkova O.A. γ-H2AX detection in peripheral blood lymphocytes, splenocytes, bone marrow, xenografts, and skin. Methods Mol. Biol. 2011, 682:249-270.
82. Revet I., Feeney L., Bruguera S., Wilson W., Dong T.K., Oh D.H., Dankort D., Cleaver J.E. Functional relevance of the histone gammaH2AX in the response to DNA damaginig agents. Proc. Natl. Acad. Sci. USA 2011, 108:8663-8667.
83. Rothkamm K., Löbrich M. Evidence for a lack of DNA double-strand break repair in human cells exposed to very low x-ray doses. Proc. Natl. Acad. Sci. USA 2003, 100:5057-5062.
84. Rothkamm K., Horn S. γ-H2AX as protein biomarker for radiation exposure. Ann. Ist. Super. Sanità 2009, 45:265-271.
85. Rothkamm K, Crosbie J.C., Daley F., Bourne S., Barber P.R., Vojnovic B., Cann L., Rogers P.A.W. in situ biological dose mapping estimates the radiation burden delivered to "spared" tissue between synchrotron X-ray microbeam radiotherapy tracks. PLoS One 2012, 7:e29853.
86. Rothkamm K., Horn S., Scherthan H., Rößler U., De Amicis A., Barnard S., Kulka U., Lista F., Meineke V., Braselmann H., Beinke C., Abend M. Laboratory intercomparison on the γ-H2AX foci assay. Radiat. Res. 2013, 180:149-155.
87. Rothkamm K., Barnard S., Ainsbury E.A., Al-hafidh J., Barquinero J.F., Lindholm C., Moquet J., Perälä M., Roch-Lefèvre S., Scherthan H., Thierens H., Vral A., Vandersickel V. Manual versus automated γ-H2AX foci analysis across five European laboratories: can this assay be used for rapid biodosimetry in large scale radiation accident?. Mutat. Res. 2013, 765:170-173.
88. Rowney N.C., Johnson A.C., Williams R.J. Cytotoxic drugs in drinking water: a prediction and risk assessment exercise for the Thames catchment in the United Kingdom. Environ. Toxicol. Chem. 2009, 28:2733-2743.
89. Rydberg B. Radiation-induced heat-labile sites that convert into DNA double-strand breaks. Radiat. Res. 2000, 153:805-812.
90. Sanderson H., Brain R.A., Johnson D.J., Wilson C.J., Solomon K.R. Toxicity classification and evaluation of four pharmaceuticals classes: antibiotics, antineoplastics, cardiovascular, and sex hormones. Toxicology 2004, 203:27-40.
91. Sarkar A., Day D., Shrivastava A.N., Sarker S. Molecular biomarkers: their significance and application in marine pollution monitoring. Ecotoxicology 2006, 15:333-340.
92. Schvartzman J.B., Goyanes V. A new method for identification of SCE[U+05F3]s per cell cycle in BrdUrd-substituted chromosomes. Cell Biol. Int. Rep. 1980, 4:415-423.
93. Sedelinkova O.A., Horikawa I., Redon C., Nakamura A., Zimonjic D.B., Popescu N.C., Bonner W.M. Delayed kinetics of DNA double-strand break processing in normal and pathological aging. Aging Cell 2008, 7:89-100.
94. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat. Rev. Cancer 2003, 3:155-168.
95. Showalter S.L., Showalter T.N., Witkiewicz A., Havens R., Kennedy E.P., Hucl T., Kern S.E., Yeo C.J., Brody J.R. Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil. Is it time to move on?. Cancer Biol. Ther. 2008, 7:986-994.
96. Siddik Z.H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003, 22:7265-7279.
97. Simonsson M., Qvarnström F., Nyman J., Johansson K.A., Garmo H., Turesson I. Low-dose hypersensitive gammaH2AX response and infrequent apoptosis in epidermis from radiotherapy patients. Radiother. Oncol. 2008, 88:388-397.
98. Smart D.J., Halicka H.D., Schmuck G., Traganos F., Darzynkiewicz Z., Williams G.M. Assessnebt of DNA double-strand breaks and γH2AX induced by the topoisomerase II poisons etoposide and mitoxantrone. Mutat. Res. 2008, 641:43-47.
99. Smart D.J., Ahmedi K.P., Harvey J.S., Lynch A.M. Genotoxicity sreening via the γH2AX by flow assay. Mutat. Res. 2011, 715:25-31.
100. Soutoglou E., Mistreli T. Activation of the cellular DNA damage response in the absence of DNA lesions. Science 2008, 320:1507-1510.
101. Srivastava N., Gochhait S., de Boer P., Bamezai R.N.K. Role of H2AX in DNA damage response and human cancers. Mutat. Res. 2009, 681:180-188.
102. Srivastava N., Manvati S., Srivastava A., Pal R., Kalaiarasan P., Chattopadhyay S., Sailesh G., Dua R., Bamesai R.N.K. miR-24-2 controls H2AFX expression regardless of gene copy number alternation and induces apoptosis by targeting antiapoptotic gene BCL-2: a potential for therapeutic intervention. Breast Cancer Res. 2011, 13:R39.
103. Suspiro A., Prista J. Biomarkers of occupational exposure do anticancer agents: a minireview. Toxicol. Lett. 2011, 207:42-52.
104. Tanaka T., Munshi A., Brooks C., Liu J., Hobbs M.L., Meyn R.E. Gefitinib radiosensitizes non-small cell lung cancer cells by suppressing cellular DNA repair capacity. Clin. Cancer Res. 2008, 15:1266-1273.
105. Terai K., Dong G.Z., Park M.T., Gu Y., Song C.W., Park H.J. Cisplatin enhances the anticancer effect of beta-lapachone by upregualting NQO1. Anticancer Drugs 2009, 20:901-909.
106. Terwogt J.M., Schellens J.H., Huinink W.W., Beijnen J.H. Clinical pharmacology of anticancer agents in relation to formulations and administration routes. Cancer Treat. Rev. 1999, 25:83-101.
107. Tice R.R., Agurell E., Anderson D., Burlinson B., Hartmann A., Kobayashi H., Miyamae Y., Rojas E., Ryu J.C., Sasaki Y.F. Single cell gell/comet assay: Guidelines for in vitro and in vivo genetic toxicology testing. Eviron. Mol. Mutagen 2000, 35:206-221.
108. Tomasz M. Mitomycin C: small, fact and deadly (but very selective). Chem. Biol. 1995, 2:575-579.
109. Toyooka T., Ibuki Y. New method for testing phototoxicity of polycyclic aromatic hydrocarbons. Environ. Sci. Technol. 2006, 40:3603-3608.
110. Toyooka T., Ibuki Y. Cigarette sidestream smoke induces phosphorylated histone H2AX. Mutat. Res. 2009, 676:34-40.
111. Turner H.C., Brenner D.J., Chen Y., Bertucci A., Zhang J., Wang H., Lyulko O.V., Xu Y., Shuryak I., Schaefer J., Simaan N., Randers-Pherson G., Yao Y.L., Amundson S.A., Garty G. Adapting the γ-H2AX assay for automated processing in human lymphocytes. 1. Technological aspects. Radiat. Res. 2011, 175:282-290.
112. Valdiglesias V., Giunta S., Fenech M., Neri M., Bonassi S. γH2AX as a marker of DNA double strand breaks and genomic instability in human population studies. Mutat. Res. 2013, 753:24-40.
113. Valente M., Voisin P., Laloi P., Roy L., Roch-Lefèvre S. Automated gamma-H2AX focus scoring method for human lymphocytes after radiation exposure. Radiat. Meas. 2011, 46:871-876.
114. Vandersickel V., Depuydt J., Van Bockstaele B., Perletti G., Philipe J., Thierens H., Vral A. Early increase of radiation-induced γH2AX foci in a human Ku70/80 knockdown cell line characterized by an enhanced radiosensitivity. J. Rad. Res. 2010, 51:633-641.
115. Wan R., Mo Y., Feng L., Chien S., Tollerund D.J., Zhang Q. DNA damage caused by metal nanoparticles: involvement of oxidative stress and activation of ATM. Chem. Res. Toxicol. 2012, 25:1402-1411.
116. Watters G.P., Smart D.J., Harvey J.S., Austin C.A. H2AX phosphorylation as a genotoxicity endpoint. Mutat. Res. 2009, 679:50-58.
117. Wu J., Clingen P.H., Spanswick V.J., Mellinas-Gomez M., Meyer T., Puzanov I., Jodrell D., Hochhauser D., Hartley J.A. Clin. Cancer Res. 2013, 19:721-730.
118. Yin J., Yang Y., Li K., Zhang J, Shao B. Analysis of anticancer drugs in sewage water by selective SPE and UPLC-ESI-MS-MS. J. Chromatogr. Sci. 2010, 48:781-789.
119. World Health Organization (WHO), 2011. Pharmaceuticals in drinking water. WHO Press, Geneva, Switzerland.
120. Yu L., Yan Z., Quan C., Ji W., Zhu J., Huang Y., Guan R., Sun D., Jin Y., Meng X., Zhang C., Yu Y., Bai J., Sun W., Fu S. Gemcitabine eliminates double minute chromosomes from human ovarian cancer cells. PLoS One 2013, 8:e71988.
121. Yuan J., Adamski R., Chen J. Focus on histone variant H2AX: To be or not to be. FEBS Lett. 2010, 584:3717-3724.
122. Zhang J., Chang V.W.C., Giannis A., Wang J.Y. Removal of cytostatic drugs from aquatic environment: a review. Sci. Total Environ. 2013, 445-446:281-298.
123. Zounková R., Odráška P., Doležalová L., Hilscherová K., Maršálek B., Bláha L. Ecotoxicity and genotoxicity assessment of cytostatic pharmaceuticals. Environ. Toxicol. Chem. 2007, 26:2208-2214.
124. Zounková R., Kovalova L., Bláha L., Dott W. Ecotoxicology and genotoxicity assessment of cytotoxic antineoplastic drugs and their metabolites. Chemosphere 2010, 81:253-260.